Latest News

(UroToday.com) At the 2020 European Society for Medical Oncology Virtual Congress (ESMO) virtual annual meeting, Dr. Laurence Albiges provided a discussant presentation for the COSMIC-021 trial and the French BIONIKK trial. The first trial she discussed was presented by Dr. Monty Pal “Cabozantinib in combination with atezolizumab as first-line therapy for advanced clear cell renal cell […]

(UroToday.com) Treatment options for patients with advanced prostate cancer have changed dramatically over the past 10 years. In almost all circumstances, the pivotal phase III trials supporting the use of newer agents have compared active treatment to placebo. This lack of head-to-head trials, along with many guidelines supported treatment approaches has introduced significant uncertainty in […]

Alicia Morgans:  Hi, this is Alicia Morgans, GU Medical Oncologist, and Associate Professor of Medicine at Northwestern University. I am so excited to have here with me today, a friend and colleague, Dr. Toni Choueiri, who is a Professor of Medicine at the Harvard Medical School, as well as being the Director of the Lank […]

(UroToday.com) Many immunotherapy strategies have been pursued in mCRPC to date, with the dendritic cell vaccine sipuleucel-T representing the only approved therapy in this space. Recently, updated overall survival data from the CA184-043 trial of ipilimumab following radiotherapy to bone metastases in patients who had progressed on docetaxel suggested improved overall survival relative to placebo1 (plot […]

(UroToday.com) Dr. Andrea Alimonti summarized the results from two novel therapeutic strategies aimed at improving outcomes in men with castration-resistant prostate cancer. He began his talk by showing a published figure showing genomic and immune characteristics of tumors across the spectrum of disease as well as management strategies.

(UroToday.com) In this presentation, Dr. Guilia Baciarello summarized two presentations describing the clinical and genomic characteristics of patients with penile cancer, and one analyzing the risk of secondary testicular cancer.

(UroToday.com) Dr. Eleni Efstathiou summarized three abstracts focusing on various aspects of prostate cancer management in the context of DNA damage repair alterations. DNA damage repair (DDR) alterations, specifically those resulting in homologous recombination repair deficiency (HRD).

(UroToday.com) Dr. Walter Berger began his review with abstract 700O, the authors tested the predictive ability of three signatures: (1) a gene expression signature consistent with Teffector activity from IMmotion150 that when present enriched for responders to atezolizumab and bevacizumab. (2) a gene expression signature suggestive of Angiogenesis from IMmotion150 that when present in samples enriched for […]

(UroToday.com) The NIVOREN GETUG-AFU26 clinical trial was a real-world phase 2 multicenter study of nivolumab in metastatic clear cell renal cell carcinoma (ccRCC). Patient outcomes from this study compared favorably to the randomized phase 3 trial CheckMate 025 comparing nivolumab with everolimus, published in 2015. From the NIVOREN trial, a translational program was launched to assess […]

(UroToday.com) This poster detailed the phase 3 randomized, double-blind, multi-center ChekMate 7DX (NCT03100018) trial of nivolumab in combination with docetaxel chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). The rationale for this combination comes from preclinical and clinical evidence that docetaxel may promote antitumor immune responses by increasing tumor antigen presentation, promoting the production […]